NYSEMKT: STXSStereotaxis Inc Stock
$1.68-0.10 (-5.62%)
Updated Sep 22, 2023
STXS Price
$1.68
Fair Value Price
N/A
Market Cap
$135.86M
52 Week Low
$1.33
52 Week High
$2.75
P/E
-6.22x
P/B
6.35x
P/S
4.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$29.37M
Earnings
-$19.38M
Gross Margin
57.7%
Operating Margin
-67.47%
Profit Margin
-70.6%
Debt to Equity
1
Operating Cash Flow
-$11M
Beta
0.92
Next Earnings
Nov 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
STXS Overview
Stereotaxis Incorporated manufactures and sells robotic systems, instruments, and information system for the interventional laboratory sector in the U.S. and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe, which enable physicians to complete complex procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also offers Vdrive, a system that offers navigation and stability for diagnostic and therapeutic devices. Stereotaxis was incorporated in 1990 and is headquartered in Saint Louis, MO.
Zen Score
–
Industry Average (32)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STXS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STXS is poor value based on its book value relative to its share price (6.35x), compared to the US Medical Instruments & Supplies industry average (3.36x)
P/B vs Industry Valuation
STXS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STXS due diligence checks available for Premium users.
Be the first to know about important STXS news, forecast changes, insider trades & much more!
STXS News
Valuation
STXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.22x
Industry
49.7x
Market
14.52x
STXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.35x
Industry
3.36x
STXS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STXS's financial health
Profit margin
Revenue
$7.9M
Net Income
-$5.0M
Profit Margin
-67.3%
STXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STXS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$48.3M
Liabilities
$21.3M
Debt to equity
1
STXS's short-term assets ($38.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STXS's short-term assets ($38.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STXS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
$20.1M
Financing
-$26.0k
STXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STXS vs Medical Stocks
Stereotaxis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.